|
WO2016115482A1
|
|
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
|
WO2014130682A2
|
|
Method of analysis using array sensor
|
|
CN104822703A
|
|
Combination therapy of inhibitors for igf1r and pi3k
|
|
EP2741747A1
|
|
JAK P13K/mTOR COMBINATION THERAPY
|
|
MX2013009351A
|
|
mTOR/JAK INHIBITOR COMBINATION THERAPY.
|
|
WO2012095853A1
|
|
Modified release formulations comprising sip receptor modulators
|
|
GB0803945D0
|
|
Organic compounds
|
|
AU2007203463A1
|
|
N-phenyl-2-pyrimidine-amine derivatives
|
|
AU2007201830A1
|
|
High drug load tablet
|
|
WO2007100741A2
|
|
System for delivering nebulized cyclosporine and methods of treatment
|
|
CN101370711A
|
|
Method and apparatus for detecting presence of an ophthalmic lens in a package
|
|
GB0609915D0
|
|
Methods and compositions for assessing chronic allograft rejection
|
|
US2006255174A1
|
|
Systems and methods for controlling fluid feed to an aerosol generator
|
|
GB0606776D0
|
|
Predictive biomarkers for chronic allograft nephropathy
|
|
US2005199236A1
|
|
Methods and devices for aerosolizing medicament
|
|
CN101404988A
|
|
Breast cancer treatment regimen
|
|
US2005003004A1
|
|
Pharmaceutical formulation comprising a water-insoluble active agent
|
|
US2005022813A1
|
|
Aerosolization apparatus with rotating capsule
|
|
US2003150445A1
|
|
Apparatus and methods for delivery of medicament to a respiratory system
|
|
US7540284B2
|
|
Powder aerosolization apparatus and method
|
